E
Esperion Therapeutics
Develops and commercialises oral therapies for the treatment of patients with elevated LDL-C
About Esperion Therapeutics
Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative lipid-lowering therapies to address cardiovascular disease. The company primarily serves healthcare providers and patients who require effective treatments for managing low-density lipoprotein cholesterol (LDL-C). Operating in the pharmaceutical and biotechnology market, Esperion's business model revolves around the research, development, and commercialization of novel therapies, with a particular emphasis on bempedoic acid and its combination with ezetimibe. The company generates revenue through the sale of its FDA-approved products and potential future licensing agreements. Esperion's commitment to clinical trials and compassionate use programs underscores its dedication to advancing cardiovascular health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2003
- Employees
- 255
- Open positions
- 22
- Dealroom signal
- 28.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Became $1B as Subsidiary, Biotech and Pharma, Became Thoroughbred as Subsidiary, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Mar 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| BUYOUTOther financing | May 2026 | $1B | $1B | ArchiMed | ↗ |
| POST IPO EQUITYOther financing | Oct 2025 | $75M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Esperion Therapeutics is 19K monthly website visits, up 35.7% over the last three months. Esperion Therapeutics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Esperion Therapeutics in the Plymouth ecosystem
The Esperion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Aisling Capital
Alta Partners
Domain Associates
Arboretum Ventures
Longitude Capital
Asset Management Ventures
Series B and later3 investors entered at this stage
Pfizer
Oberland Capital
ArchiMed
Other known investors1 additional known investor
HealthCap
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Esperion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Esperion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










